VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
TV005
Phase 2
Biologic
N
National Institute of Allergy and Infectious Diseases (NIAID)
1
Indications
3
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Infection
1 trial
Dengue Controlled Human Infection Model in Dhaka, Bangladesh
Active, not recruiting
·
B
Beth Kirkpatrick
·
Phase 2
·
NCT05229354
·
192 enrolled
Safety and Efficacy
1 trial
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
Completed
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 1
·
NCT02317900
·
48 enrolled
Immunogenicity
1 trial
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Completed
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 2
·
NCT02678455
·
192 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for TV005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
TV005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for TV005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 2
[1]
Company
N
National Institute of Allergy and Infectious Diseases (NIAID)
Related News